Jaguar Health Announces Release of Podcast Interview with The Wall Street Resource

Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) has released a podcast interview with CEO Lisa Conte via The Wall Street Resource. The company focuses on developing plant-based, non-opioid medications for gastrointestinal issues, particularly targeting chronic diarrhea. Their flagship product, Mytesi (crofelemer), is FDA-approved for treating non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company emphasizes sustainable sourcing of ingredients, highlighting ecological integrity in harvesting practices.

Positive

• Mytesi is FDA-approved for non-infectious diarrhea in HIV/AIDS patients.
• Jaguar focuses on plant-based, sustainable medicines.

Negative

• Potential risks associated with non-treatment of infectious diarrhea.
• Adverse reactions in clinical studies include upper respiratory issues.

SAN FRANCISCO, CA / ACCESSWIRE / November 24, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, today announced the release of a podcast interview conducted by Jaguar's founder, president, and CEO, Lisa Conte, with The Wall Street Resource.

To listen to the interview, go to https://thewallstreetresource.com/webcasts

About The Wall Street Resource

The Wall Street Resource.com is a paid publishing platform for microcap discovery and due diligence, and a resource for webcast interviews of CEOs and executives. For more information, please visit www.thewallstreetresource.com.

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commmercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi^® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

About Mytesi^®

Mytesi^® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi^® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi^®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi^®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View source version on accesswire.com:
https://www.accesswire.com/618037/Jaguar-Health-Announces-Release-of-Podcast-Interview-with-The-Wall-Street-Resource

FAQ

What is the significance of Jaguar Health's podcast interview released on November 24, 2020?

The podcast features CEO Lisa Conte discussing the company's focus on plant-based medications and their FDA-approved product, Mytesi.

What is Mytesi and its indication?

Mytesi (crofelemer) is an FDA-approved treatment for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

How does Jaguar Health ensure sustainability in its product sourcing?

Jaguar Health implements a sustainable harvesting program for its key ingredient, crofelemer, sourced from the Amazon rainforest.

What are the common adverse reactions associated with Mytesi?

Common adverse reactions include upper respiratory tract infection (5.7%), bronchitis (3.9%), and cough (3.5%).